Sökning: onr:"swepub:oai:DiVA.org:umu-150715" > Effect of simvastat...
Fältnamn | Indikatorer | Metadata |
---|---|---|
000 | 03663naa a2200481 4500 | |
001 | oai:DiVA.org:umu-150715 | |
003 | SwePub | |
008 | 180816s2018 | |||||||||||000 ||eng| | |
024 | 7 | a https://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-1507152 URI |
024 | 7 | a https://doi.org/10.1016/j.atherosclerosis.2018.03.0302 DOI |
040 | a (SwePub)umu | |
041 | a engb eng | |
042 | 9 SwePub | |
072 | 7 | a ref2 swepub-contenttype |
072 | 7 | a art2 swepub-publicationtype |
100 | 1 | a Hodges, Gethin W.4 aut |
245 | 1 0 | a Effect of simvastatin and ezetimibe on suPAR levels and outcomes |
264 | 1 | b ELSEVIER IRELAND LTD,c 2018 |
338 | a print2 rdacarrier | |
520 | a Background and aims: Soluble urokinase plasminogen activator receptor (suPAR) is an inflammatory marker associated with cardiovascular disease. Statins lower both low-density lipoprotein (LDL)-cholesterol and C-reactive protein (CRP), resulting in improved outcomes. However, whether lipid-lowering therapy also lowers suPAR levels is unknown.& para;& para;Methods: We investigated whether treatment with Simvastatin 40 mg and Ezetimibe 10 mg lowered plasma suPAR levels in 1838 patients with mild-moderate, asymptomatic aortic stenosis, included in the Simvastatin and Ezetimibe in Aortic Stenosis (SEAS) study, using a pattern mixture model. A 1-year Cox analysis, adjusted for established cardiovascular risk factors, allocation to study treatment, peak aortic valve velocity and baseline suPAR, was performed to evaluate relationships between change in suPAR with all-cause mortality and the composite endpoint of major cardiovascular events (MCE) composed of ischemic cardiovascular events (ICE) and aortic valve related events (AVE).& para;& para;Results: After 4.3 years of follow-up, suPAR levels had increased by 9.2% (95% confidence interval [CI]: 7.0%-11.5%) in the placebo group, but only by 4.1% (1.9%-6.2%) in the group with lipid-lowering treatment (p<0.001). In a multivariate 1-year analysis, 1-year suPAR was strongly associated with all-cause mortality, hazard ratio (HR) = 2.05 (1.17-3.61); MCE 1.40 (1.01-1.92); and AVE 1.42 (1.02-1.99) (all p<0.042) for each doubling of suPAR; but was not associated with ICE.& para;& para;Conclusions: Simvastatin and Ezetimibe treatment impeded the progression of the time-related increase in plasma suPAR levels. Year-1 suPAR was associated with all-cause mortality, MCE, and AVE irrespective of baseline levels (SEAS study: NCT00092677). (C) 2018 Elsevier B.V. All rights reserved. | |
650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Kardiologi0 (SwePub)302062 hsv//swe |
650 | 7 | a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Cardiac and Cardiovascular Systems0 (SwePub)302062 hsv//eng |
653 | a Atherosclerosis | |
653 | a Biomarker | |
653 | a Cardiovascular disease | |
653 | a Cardiovascular risk | |
653 | a Inflammation | |
653 | a Statins | |
653 | a SuPAR | |
700 | 1 | a Bang, Casper N.4 aut |
700 | 1 | a Forman, Julie L.4 aut |
700 | 1 | a Olsen, Michael H.4 aut |
700 | 1 | a Boman, Kurtu Umeå universitet,Medicin4 aut0 (Swepub:umu)kubo0001 |
700 | 1 | a Ray, Simon4 aut |
700 | 1 | a Kesaniemi, Y. Antero4 aut |
700 | 1 | a Eugen-Olsen, Jesper4 aut |
700 | 1 | a Greve, Anders M.4 aut |
700 | 1 | a Jeppesen, Jorgen L.4 aut |
700 | 1 | a Wachtell, Kristian4 aut |
710 | 2 | a Umeå universitetb Medicin4 org |
773 | 0 | t Atherosclerosisd : ELSEVIER IRELAND LTDg 272, s. 129-136q 272<129-136x 0021-9150x 1879-1484 |
856 | 4 8 | u https://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-150715 |
856 | 4 8 | u https://doi.org/10.1016/j.atherosclerosis.2018.03.030 |
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.